PPARα与非酒精性脂肪肝被引量：9

PPARαand nonalcoholic fatty liver disease

在线阅读下载PDF

导出

摘要非酒精性脂肪肝(NAFLD)在临床上的发病率呈逐年上升趋势,PPARα高表达于肝脏,与配体结合后,再与视黄酸类受体(RXR)形成异二聚体,然后与过氧化物酶体增殖物反应元件(PPRE)结合,可以改善胰岛素抵抗及高脂血症,从而控制NAFLD的发生。对PPARα及其配体的进一步深入研究,必将为临床防治NAFLD提供新的思路。 The prevalence of nonalcoholic fatty liver disease（NAFLD） has been increasing gradually, peroxisome proliferator-activated receptor（PPAR）-α is a ligand-activat＇ed transcriptional factor that belongs to the superfamily of nuclear receptors, and expressed highly in liver. PPARα can bind to peroxisome proliferator response element（PPRE） in the promoter of target genes as an obligate heterodimer with retinoid X receptor（RXR）. After activated by its agonists, PPARα can improve insulin resistance and hyperlipidemia, and may regulate the pathogenesis of nonalcoholic fatty liver disease. With further studies on PPARα and its ligands, new idea may be provided for the prevention and treatment of nonalcoholic fatty liver disease.

作者高爱滨肖谦

机构地区重庆医科大学附属第一医院老年科

出处《国际消化病杂志》 CAS 2007年第1期18-21,共4页 International Journal of Digestive Diseases

关键词 PPARΑ 非酒精性脂肪肝胰岛素抵抗高脂血症 PPARα Nonalcoholic fatty liver disease Insulin esistance Hyperlipidemia

分类号 R575.5 [医药卫生—消化系统]

作者简介 E-mail：gaoaibin04@126．com

引文网络
相关文献

参考文献19

1Zafrani ES.Non-alcoholic fatty liver disease:an emerging pathological spectrum.Virchows Arch,2004.444:3-12
2Ferré P.The biology of peroxisome proliferators-activated receptors:relationship with lipid metabolism and insulin sensitivity.Diabetes,2004,53:43-50
3Ricote M,Valledor AF,Glass CK.Decoding transcriptional promgrams regulated by PPARs and LXRs in the macrophage:effects on lipid homeostasis,inflammation,and atherosclerosis.Arterioscler Thromb Vasc Biol,2004,24:230-239
4Duez H,Lefebvre B,Poulain P,et al.Regulation of human ApoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-Activated receptor[alpha] modulation.Arterioscler Thromb Vasc Biol,2005,25:585-591
5Day CP.Pathogenesis of steatohepatitis.Best Pract Res Clin Gastroenterol,2002,16:663-678
6van Hoek B.Non-alcoholic fatty liver disease:a brief review.Scand J Gastroenterol Suppl,2004,241:56-59
7Sanyal AJ,Campbell-Sargent C,Mirshahi F,et al.Nonalcoholic steatohepatitis:association of insulin resistance and mitochondrial abnormalities.Gastroenterology,2001,120:1183-1192
8Ruth M,Peter HJ.The metabolic syndrome and type 2 diabetes:role of the adipocyte.Curr Opin Lipidol,2003,14:549-553
9Holness MJ,Smith ND,Greenwood GK,et al.Acute (24 h)activation of peroxisome proliferator-activated Receptor-a (PPARα) reverses high-fat feeding-induced insulin hypersecretion in vivo and in perifused pancreatic islets.J Endocrinol,2003,177:197-205
10Miller AR,Otto K,Hawkins E,et al.A PPAR a/γ dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.Molecular Endocrinology,2005,19:1593-1605